Table of Contents Table of Contents
Previous Page  274 / 916 Next Page
Show Menu
Previous Page 274 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302

been accepted as a valuable outcome measure in many psychiatric

conditions; thus, identification of contributing factors may help to

improve overall outcome. Moreover, close monitoring of adverse

effects of illness on QoL in healthy siblings may become a part of

larger prevention strategies.

Supported by the grant projects MH CR AZV 15-28998A, MEYS


Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


[1] Bowman S, Alvarez-Jimenez M, Wade D, Howie L, McGorry P.

The impact of first episode psychosis on sibling quality of life.

Soc Psychiatry Psychiatr Epidemiol 2014;49:1071–81.


Diagnosis of predominant negative

symptoms: Post-hoc analyses of a

phase 3 clinical trial with cariprazine

monotherapy and risperidone

I. Laszlovszky

, Á. Barabássy , E. Szalai , B. Szatmári , J. Harsányi ,

G. Németh

Gedeon Richter Plc, Medical Division, Budapest, Hungary

Corresponding author.


To present, post hoc analyses from a controlled,

prospective study of predominant negative symptoms (PNS) of

schizophrenia on baseline patient characteristics, severity of symp-

toms and their variability among participating countries.


Data were analyzed from a phase 3, randomized,

double-blind, active-controlled, parallel-group study in adult PNS

patients with schizophrenia (EudraCT Number 2012-005485-36).

Subjects with a PANSS factor score for negative symptoms (PANSS-


24 and no pseudo-specific factors (e.g. high positive

symptoms, extrapyramidal symptoms, depression) were random-

ized to cariprazine 4.5mg/d (dose range: 3–6mg/d) or risperidone

4mg/d (dose range: 3–6mg/d) for 26 weeks. Baseline values of

PANSS-FSNS, individual PANSS items, personal and social perfor-

mance (PSP), and clinical global impression of severity (CGI-S) were

analyzed based on the data gained from 11 European participating



Average PANSS-FSNS of patients was 27.6


2.48, reflect-

ing severe negative symptoms. Patients were moderately ill (CGI-S



0.75), with marked difficulties (PSP 48.4


10.78) predomi-

nantly in social functioning. The investigated patient population

was fairly homogeneous as shown by small variability in all three

scores. Moreover, baseline values in the 11 countries presented low

variability while number of enrolled patients per country showed

high variance (


= 7–118). Narrative description of symptoms and

individual PANSS items rated as most severe and prominent were

in high correlation.


Post hoc evaluation of this predominant negative

symptom study showed that, this patient population can be identi-

fied reliably by psychiatrist. Additional training on the judgment

of personal and social relationships can increase the diagnostic


Disclosure of interest

Employee of Gedeon Richter Plc.


Day-to-day and social functioning of

patients with negative symptoms of

schizophrenia: Post-hoc analyses of a

phase 3 clinical trial with cariprazine

monotherapy and risperidone

Á. Barabássy

, I. Laszlovszky , B. Szatmári , E. Szalai , J. Harsányi ,

G. Németh

Gedeon Richter Plc, Medical Division, Budapest, Hungary

Corresponding author.


Negative symptoms have substantial impact on

day-to-day functioning of patients with schizophrenia affecting

their ability to perform activities of daily living and to maintain

personal relationships.


To present post hoc data on day-to-day and social func-

tioning of patients with predominant negative symptom (PNS) of

schizophrenia, treated with cariprazine versus risperidone.


Data from 26 weeks, phase 3, randomized, double-

blind, active-controlled study in PNS patients were analyzed

(EudraCT 2012-005485-36). Subjects with PNS (PANSS factor score

for negative symptoms

24) were randomized to cariprazine

4.5mg/d or risperidone 4mg/d. Change from baseline to end of

treatment on the personal and social performance scale (PSP) and

PANSS prosocial subscale (P3, P6, N2, N4, N7, G16) was analyzed.


Significantly greater improvements were seen with

cariprazine compared to risperidone in the change frombaseline to

end of treatment on the PSP (LSMD + 4.632 [2.71, 6.56];


< 0.001)

from week 10 onwards (effect size 0.48); in the PSP subdomains of

self-care (LSMD

0.2 [




= 0.004), personal and social

relationships (LSMD

0.2 [




< 0.001) and socially use-

ful activities (LSMD

0.4 [




< 0.001); in the number

of patients who improved at least 10 points on the PSP (OR 2.1;


= 0.001) or shifted to a higher category (OR 2.2;


= 0.001); and on

the PANSS prosocial subscale (LSMD

0.8 [




= 0.014).


Post hoc evaluation of this study showed that

cariprazine treatment is associated with a clinically relevant

improvement in patient functioning and social competence com-

pared to risperidone.

Disclosure of interest

Employee of Gedeon Richter Plc.


The relationship between negative

symptoms and cognitive functioning

in patients with an at risk mental

state for psychosis

L. Leanza

, L. Egloff , E. Studerus , C. Andreou , U. Heitz , K. Beck ,

S. Menghini-Müller , S. Ittig , A. Riecher-Rössler

University of Basel Psychiatric Hospital, Center for Gender Research

and Early Detection, Basel, Switzerland

Corresponding author.


Negative symptoms and cognitive impairments are

both present in patientswith an at riskmental state (ARMS) for psy-

chosis and negatively affect functioning and outcome. According

to previous studies in patients with first-episode psychosis, nega-

tive symptoms are negatively associatedwith cognitive functioning

while positive symptoms do not seem to be associated. Yet, little

is known about the specific relationship of negative symptoms and

cognitive functioning in ARMS patients.


To evaluate, the relationship between negative symp-

toms and cognitive functioning in ARMS patients.


Data of 154 ARMS patients were collected within the

prospective Basel early detection of psychosis (FePsy) study. Neg-

ative symptoms were assessed with the SANS, positive psychotic

symptoms with the BPRS, cognitive functioning with an extensive

neuropsychological test battery. Multiple regressions were applied

and results were controlled for age and gender.


Regression analyses showed a significant, negative asso-

ciation between negative but not positive psychotic symptoms and

cognitive functioning, showing the strongest association with ver-

bal fluency (see

Fig. 1 ).

However, results mainly did not withstand

correction for multiple testing.